Ondine Biomedical Inc
LSE:OBI
Ondine Biomedical Inc
Tax Provision
Ondine Biomedical Inc
Tax Provision Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Ondine Biomedical Inc
LSE:OBI
|
Tax Provision
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Titan Medical Inc
TSX:TMD
|
Tax Provision
-$27k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Profound Medical Corp
TSX:PRN
|
Tax Provision
$2k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Nanalysis Scientific Corp
XTSX:NSCI
|
Tax Provision
CA$11k
|
CAGR 3-Years
-67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Theralase Technologies Inc
XTSX:TLT
|
Tax Provision
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
MedMira Inc
XTSX:MIR
|
Tax Provision
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Ondine Biomedical Inc
Glance View
Ondine Biomedical, Inc. operates as a life sciences company that develops photodisinfection-based therapies to address drug-resistant infections. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-12-06. The firm is focused on developing products that utilizes its light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides a spectrum of antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The company offers solution in Steriwave Nasal Decolonization (ND) and SurgENT. Steriwave ND provides a spectrum antimicrobial providing targeted decolonization. SurgENT is a tool for cleaning and irrigating the paranasal sinuses. The intrasinus balloon design directs irrigant circumferentially around the sinus walls, maintaining debridement pressure.
You don't have any saved screeners yet